A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.

A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.
复制标题

DOI:
10.1038/s41467-021-20900-6
复制
发表时间:
2021-01-28
影响因子:
16.6
通讯作者:
Mitsuya H
Mitsuya H
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Hattori SI;Higashi-Kuwata N;Hayashi H;Allu SR;Raghavaiah J;Bulut H;Das D;Anson BJ;Lendy EK;Takamatsu Y;Takamune N;Kishimoto N;Murayama K;Hasegawa K;Li M;Davis DA;Kodama EN;Yarchoan R;Wlodawer A;Misumi S;Mesecar AD;Ghosh AK;Mitsuya H

文献摘要

参考文献

被引文献

相似文献

除雷米昔韦外,目前还没有针对SARS-CoV-2感染的特效抗病毒药物。在这里,我们表征了两个小分子化合物,命名为GRL-1720和5h,分别含有吲哚和吲哚部分,它们针对SARS-CoV-2主要蛋白酶(MPRO)。以VeroE6细胞为基础,采用核糖核酸定量聚合酶链式反应、细胞病理学和免疫细胞化学等方法,发现两个化合物对GRL-1720和GRL-1720的EC50值分别为15 ± 4和4.2 ± 0.7μM。雷美地韦在高浓度下允许病毒突破;然而,化合物5h在体外完全阻止SARS-CoV-2感染,而没有病毒突破或检测到的细胞毒性。5h联合瑞德韦对SARS-CoV-2有协同作用。X-射线结构分析表明,5H与MPRO形成共价键,并与多个活性中心氨基酸残基发生极性相互作用。提示5h可能是SARS-CoV-2感染治疗药物开发中的一种主要的MPRO抑制剂。在这里,作者利用体外试验和结构分析,表征了两个小分子的抗SARS-CoV-2性质,表明它们结合和靶向病毒主要蛋白酶(MPRO),并在体外与瑞希韦联合显示出协同抗病毒作用。
Except remdesivir, no specific antivirals for SARS-CoV-2 infection are currently available. Here, we characterize two small-molecule-compounds, named GRL-1720 and 5h, containing an indoline and indole moiety, respectively, which target the SARS-CoV-2 main protease (Mpro). We use VeroE6 cell-based assays with RNA-qPCR, cytopathic assays, and immunocytochemistry and show both compounds to block the infectivity of SARS-CoV-2 with EC50 values of 15 ± 4 and 4.2 ± 0.7 μM for GRL-1720 and 5h, respectively. Remdesivir permitted viral breakthrough at high concentrations; however, compound 5h completely blocks SARS-CoV-2 infection in vitro without viral breakthrough or detectable cytotoxicity. Combination of 5h and remdesivir exhibits synergism against SARS-CoV-2. Additional X-ray structural analysis show that 5h forms a covalent bond with Mpro and makes polar interactions with multiple active site amino acid residues. The present data suggest that 5h might serve as a lead Mpro inhibitor for the development of therapeutics for SARS-CoV-2 infection. Here, using in vitro assays and structural analysis, the authors characterize the anti-SARS-CoV-2 properties of two small molcules, showing these to bind and target the virus main protease (Mpro), and to exhibit a synergistic antiviral effect when combined with remdesivir in vitro.
DOI: 10.1056/nejmoa2001316
发表时间: 2020-03-26
影响因子: 158.5
作者:
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者: Feng, Zijian
DOI: 10.1016/s0065-7743(06)41011-3
发表时间: 2007-02-01
影响因子: --
作者:
Ghosh, Arun K.;Xi, Kai;Johnson, Michael E.;Baker, Susan C.;Mesecar, Andrew D.
通讯作者: Mesecar, Andrew D.
DOI: 10.1074/jbc.m109.095851
发表时间: 2010-09-03
期刊: The Journal of biological chemistry
影响因子: --
作者:
Li C;Qi Y;Teng X;Yang Z;Wei P;Zhang C;Tan L;Zhou L;Liu Y;Lai L
通讯作者: Lai L
DOI: 10.1128/jvi.79.24.15199-15208.2005
发表时间: 2005-12-01
影响因子: 5.4
作者:
Lindner, HA;Fotouhi-Ardakani, N;Ménard, R
通讯作者: Ménard, R
DOI: 10.1074/jbc.m310875200
发表时间: 2004-01-16
期刊: The Journal of biological chemistry
影响因子: --
作者:
Fan K;Wei P;Feng Q;Chen S;Huang C;Ma L;Lai B;Pei J;Liu Y;Chen J;Lai L
通讯作者: Lai L